Micafungin Teva (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is required for synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. Disruption of cell‑wall formation leads to osmotic instability and fungal cell death.

The dosage of Micafungin Teva is determined by the prescribing clinician based on the specific indication, severity of infection, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of micafungin during pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Micafungin Teva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis or polyenes that bind membrane sterols. Echinocandins generally have a favorable safety profile and are effective against many Candida species, including some azole‑resistant strains.

Micafungin Teva should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Once reconstituted, use according to the manufacturer’s stability guidelines.

Micafungin is administered by intravenous infusion, typically over 60 minutes. The infusion rate and duration are determined by the prescriber based on the indication and patient tolerance. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious adverse events include severe hepatic dysfunction, anaphylactic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, marked hypotension, acute renal failure, and cardiac arrhythmias. Patients should be monitored for signs of liver injury, allergic reactions, and hemodynamic changes during and after infusion.

Micafungin is contraindicated in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is advised in patients with severe hepatic impairment, and it should be avoided in those with a history of severe allergic reactions to echinocandins.